ProActive News Room is an investment web log focused on emerging small and micro-cap companies from the healthcare sector and the ProActive HavRx global stock indexes.
Editor reviews are provided by professional editors who evaluate a blog based on the following criteria: Frequency of Updates, Relevance of Content, Site Design, and Writing Style.
Below is a summary of BioMed updates from 2-Dec, summarized in 140 characters or less each.
$ELTP.OB / Elite Pharma soars 40% on FDA generic approval opiate pain drug methadone along with ThePharmaNetwork
$JAV / Javelin Pharma files NDA for FDA...
Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company's clinical-stage pipeline is based on...
In an option agreement announced today with MD Anderson Medical Center, ImmunoCellular Therapeutics (OTC: IMUC.OB) has acquired the rights to novel peptides that elicit a T-cell immune response against validated cancer stem cell targets known as the...
Click here to follow me on twitter / mikehavrilla and check out the BioMedReports.com FDA Calendar service, which includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA...
On 11/27/09, Theravance (NASDAQ: THRX) announced that it received a Complete Response Letter (CRL) from the FDA for the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP). VIBATIV (telavancin) is approved in the...
